Peptinovo Biopharma, a biotechnology company pioneering targeted cancer therapies through its proprietary PALM nanotechnology, has announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) and bioanalytical contract research organization (CRO) enabling precision medicines and other complex therapies. Ardena will manufacture Peptinovo’s cancer drug-delivery nanotechnology for the company’s planned launch of human clinical trials by year end.

Securing an established manufacturing partner marks a critical milestone for Peptinovo. Manufacturing stability is essential to move breakthrough science from the lab to patients, and Ardena’s expertise provides the assurance of scalability, repeatability, and quality required for global clinical development.

“Partnering with Ardena is a huge step forward for Peptinovo because it demonstrates we have achieved the level of manufacturing stability that is so vital in this industry,” Peptinovo Biopharma CEO Steve Tokarz said.

Peptinovo’s proprietary PALM (Peptide-Assisted Lipid Micelle) technology is designed to deliver chemotherapy agents more precisely to tumors, minimizing toxicity and maximizing therapeutic effect. Ardena will leverage its established nanomedicine expertise, pharmaceutical manufacturing and analytical capabilities, strong project management, and proven record of advancing nanoparticle-based medicines to clinical trials to support Peptinovo’s advancement to clinical trials late this year in Australia.

“We are delighted to support Peptinovo’s innovative program,” Ardena COO Gerjan Kemperman said. “Peptinovo’s technology holds great promise in advancing cancer treatment, and our experience in nanomedicine manufacturing is a strong complement to the company’s scientific platform. Together, we are striving to accelerate the development of precision medicines, advancing scientific innovation into patient impact.”